Logo

Personalis

In Brief This Week: Abbott, Personalis, Aspira Women's Health, Thermo Fisher Scientific, Illumina, More

News items for the week of Nov. 4, 2024.

Tempus AI, Personalis Expand Commercialization Partnership for MRD Test With $36M Investment

Tempus is the exclusive commercial partner for Personalis' minimal residual disease test for breast and lung cancers and for immunotherapy monitoring.

In Brief This Week: Thermo Fisher Scientific, Labcorp, Personalis, Exagen, Co-Diagnostics, More

News items for the week of Aug. 5, 2024.

Myriad Genetics, Personalis Cross-License MRD Technology

The companies inked an agreement to co-license their minimal residual disease technology in an effort to broaden testing access and boost adoption.

Personalis, Foresight Diagnostics Settle MRD Testing Patent Lawsuit

Foresight has agreed to pay royalties to Personalis for the use of certain patented methods related to tumor-informed minimal residual disease testing.

Jun 5, 2024

Minimal Residual Disease Testing Progress in Breast Cancer Highlighted at ASCO
Premium

Dec 6, 2023

Personalis Expects Accelerated Clinical Growth Under Tempus Marketing Deal
Premium

Dec 4, 2023

Personalis Cuts 65 Jobs in Continued Cost-Reduction Effort

Nov 28, 2023

Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test

Oct 24, 2023

In New TRACERx Data, Personalis MRD Test Shows Improved Sensitivity With Potential Clinical Impact
Premium

Jun 27, 2023

Personalis Sues Foresight Diagnostics Again Alleging Patent Infringement

Jun 15, 2023

Liquid Biopsy Firms Eye Melanoma for Minimal Residual Disease Testing, Though Questions Remain
Premium

May 16, 2023

Personalis, Ono Pharmaceutical, Japan National Cancer Center Partner on Opdivo Rectal Cancer Trial

May 2, 2023

Personalis to Test MRD Assay in Triple-Negative Breast Cancer Trial With ABRCC, Criterium

Apr 27, 2023

Foresight Diagnostics Closes $58.8M Series B Round

Apr 5, 2023

Personalis MRD Assays to Support UK's TRACERx ctDNA Monitoring Study

Sep 7, 2022

Larger Liquid Biopsy Panels Loom, But Patient Benefit Still Uncertain
Premium

Aug 18, 2022

Personalis Adds Newly Issued Patent to Foresight Diagnostics Infringement Suit

Aug 2, 2022

Personalis Sues Foresight Diagnostics, Alleging Patent Infringement

May 6, 2022

Personalis Building Data for High-Sensitivity Residual Cancer Assay
Premium

Feb 15, 2022

Personalis, UCSD Cancer Center Ink Clinical Genomic Testing, Research Partnership

Oct 13, 2021

Mayo Clinic, Personalis Ink Comprehensive Genomics Research Collaboration

Aug 27, 2021

In Brief This Week: Biodesix, Avisa Diagnostics, Mount Sinai, Sophia Genetics, and More

Mar 30, 2021

MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial

Feb 17, 2021

Natera, Personalis Team up for Cancer Treatment Monitoring, MRD Testing